Supercharged immune cells take on Hard-to-Treat blood cancer

NCT ID NCT07509086

Recruiting now Disease control Sponsor: The First Hospital of Jilin University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of CAR-T cell therapy, boosted with IL-15, in 25 people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, engineered to target cancer cells. The goal is to see if it can shrink tumors and improve response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IL-15-armored CAR-T cells (immune cells engineered to target cancer)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat multiple myeloma or plasma cell leukemia.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA (PCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL LEUKEMIA (PCL) RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

The First Hospital of Jilin University
RECRUITING

Changchun, Jilin, 130000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.